Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate (Q36563407)

14 August 2017

1 reference

title

Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate (English)

1 reference

14 August 2017

Charles H Chesnut

1

1 reference

PubMed ID

16903769

14 August 2017

language of work or name

1 reference

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

66

1 reference

14 August 2017

10

1 reference

14 August 2017

1351-1359

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200666100-00004

14 August 2017

0 references

cites work

The association of radiographically detected vertebral fractures with back pain and function: a prospective study

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666100-00004

Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666100-00004

Pre-existing fractures and bone mass predict vertebral fracture incidence in women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666100-00004

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666100-00004

Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness

21 January 2018

1 reference

12 December 2020

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents

1 reference

12 December 2020

Compliance with pharmacologic therapy for osteoporosis

1 reference

12 December 2020

Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Early discontinuation of treatment for osteoporosis

1 reference

12 December 2020

Guidelines for diagnosis and management of osteoporosis

1 reference

12 December 2020

Alendronate and naproxen are synergistic for development of gastric ulcers

1 reference

12 December 2020

Multiple ulcerative esophagitis caused by alendronate

1 reference

12 December 2020

Medication compliance in the elderly.

1 reference

12 December 2020

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

12 December 2020

Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group

1 reference

12 December 2020

Proportion of osteoporotic post-menopausal women at increased risk for upper GI adverse events associated with bisphosphonate therapy

1 reference

12 December 2020

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

1 reference

12 December 2020

Compliance with treatment regimens in chronic asymptomatic diseases

1 reference

12 December 2020

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

12 December 2020

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

1 reference

12 December 2020

A model of lifetime osteoporosis impact.

1 reference

12 December 2020

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

1 reference

12 December 2020

Osteoporosis prevention, diagnosis, and therapy

1 reference

12 December 2020

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

12 December 2020

Is the paradigm shifting?

1 reference

12 December 2020

Adverse effects of bisphosphonates. A comparative review

1 reference

12 December 2020

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

1 reference

12 December 2020

Oral weekly ibandronate prevents bone loss in postmenopausal women

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

Compliance with drug therapies for the treatment and prevention of osteoporosis

1 reference

12 December 2020

Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys

1 reference

12 December 2020

Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties

1 reference

12 December 2020

Osteoporosis. An overview of the National Osteoporosis Foundation clinical practice guide

1 reference

12 December 2020

Pharmacologic prevention of osteoporotic fractures.

1 reference

12 December 2020

Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint

1 reference

12 December 2020

Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs

1 reference

12 December 2020

A systematic review of the associations between dose regimens and medication compliance

1 reference

12 December 2020

The physician's role in women's decision making about hormone replacement therapy

1 reference

12 December 2020

The impact of compliance with osteoporosis therapy on fracture rates in actual practice.

1 reference

12 December 2020

The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial

1 reference

12 December 2020

Epidemiology of spinal osteoporosis

1 reference

12 December 2020

Esophageal stricture associated with alendronate therapy

1 reference

12 December 2020

Use of medications and polypharmacy are increasing among the elderly

1 reference

12 December 2020

Nonclinical model for assessing gastric effects of bisphosphonates

1 reference

12 December 2020

A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs

1 reference

12 December 2020

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

12 December 2020

The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study

1 reference

12 December 2020

A meta-analysis of previous fracture and subsequent fracture risk

1 reference

12 December 2020

Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.

1 reference

12 December 2020

Requirements for DXA for the management of osteoporosis in Europe

1 reference

12 December 2020

Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis

1 reference

12 December 2020

Exposure to potential drug interactions in primary health care

1 reference

12 December 2020

Perspective. How many women have osteoporosis?

1 reference

12 December 2020

Seven years of treatment with risedronate in women with postmenopausal osteoporosis

1 reference

12 December 2020

Vertebral fracture epidemiology

1 reference

12 December 2020

Risk of hip fracture in women with vertebral fracture

1 reference

12 December 2020

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis

1 reference

12 December 2020

Geriatrics in the United States--baby boomers' boon?

1 reference

12 December 2020

Oesophageal stricture associated with alendronic acid

1 reference

12 December 2020

Osteoporosis management: out of subspecialty practice and into primary care.

1 reference

12 December 2020

New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate

1 reference

12 December 2020

Nonadherence and osteoporosis treatment preferences of older women: a qualitative study.

1 reference

12 December 2020

Esophagitis dissecans superficialis and alendronate: case report

1 reference

12 December 2020

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

1 reference

12 December 2020

The impact of reducing dose frequency on health outcomes

1 reference

12 December 2020

Information needs in the management of osteoporosis in family practice: an illustration of the failure of the current guideline implementation process.

1 reference

12 December 2020

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats

1 reference

12 December 2020

Compliance of osteoporotic patients with different treatment regimens

1 reference

12 December 2020

Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Tolerability and compliance with risedronate in clinical practice

1 reference

12 December 2020

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

12 December 2020

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

12 December 2020

BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

1 reference

12 December 2020

Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women

1 reference

12 December 2020

The prevention and treatment of osteoporosis

1 reference

12 December 2020

Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies

1 reference

12 December 2020

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis

1 reference

12 December 2020

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

10.2165/00003495-200666100-00004

Identifiers

DOI

1 reference

PubMed ID

16903769

Dimensions Publication ID

14 August 2017

0 references

1 reference

PubMed ID

16903769